Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 201.00
Bid: 199.20
Ask: 203.50
Change: 0.00 (0.00%)
Spread: 4.30 (2.159%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 201.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

22 Sep 2020 12:54

RNS Number : 7516Z
Oxford Biomedica PLC
22 September 2020
 

 

 

 

PDMR Dealings / Market Share sale

 

Oxford, UK - 22 September 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 18 September 2020, that Dr. Jason Slingsby, Chief Business Officer of the Group, exercised options over 13,393 ordinary shares at 496.6p and sold all of the resulting shares at 845.0p. Following this transaction Dr. Slingsby holds 88,569 options and no shares in the Company.

 

Oxford Biomedica was also informed that on 18 September 2020, that Dr. James Miskin, Chief Technical Officer, sold 2,893 ordinary shares at 844.4p. In addition, Dr. Miskin exercised 9,255 DBP (2016) options at nil cost, exercised 6,402 DBP (2017) options at nil cost and sold all of the resulting shares at 845p. He also exercised 5,809 LTIP options at 50p and sold all the resulting shares at 844p. Following these transactions Dr. Miskin holds 185,434 options and no shares in the Company.

 

The issued share capital of the Group is 82,130,020 ordinary 50p shares.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Jason Slingsby

2.

Reason for the notification

a)

Position/status

Chief Business Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£4.97

13,393

 

 

e)

Aggregated information

- Aggregate volume

 

- Price

 

- Aggregated total

 

 

13,393

 

 

£4.966

 

£66,509.64

f)

Date of the transaction

2020-09-18

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Jason Slingsby

2.

Reason for the notification

a)

Position/status

Chief Business Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Disposal

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£8.45

13,393

 

 

e)

Aggregated information

- Aggregate volume

 

- Price

 

- Aggregated total

 

 

13,393

 

 

£8.45

 

£113,170.85

f)

Date of the transaction

2020-09-18

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Disposal

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£8.44

2,893

 

 

e)

Aggregated information

- Aggregate volume

 

- Price

 

- Aggregated total

 

 

2,893

 

 

£8.44405

 

£24,428.64

f)

Date of the transaction

2020-09-18

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£0.50

5,809

Nil cost

9,255

Nil cost

6,402

 

 

e)

Aggregated information

- Aggregate volume

 

- Price

 

- Aggregated total

 

 

 

21,466

 

 

£0.135

 

£2,904.50

f)

Date of the transaction

2020-09-18

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Business Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Disposal

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£8.44

5,809

£8.45

15,657

 

 

e)

Aggregated information

- Aggregate volume

 

- Price

 

- Aggregated total

 

 

21,466

 

 

£8.447

 

£181,329.61

f)

Date of the transaction

2020-09-18

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDCGUDDGGD
Date   Source Headline
20th Mar 20247:00 amRNSUpdate on CDMO Services
11th Mar 20247:00 amRNSBoard Changes
5th Mar 20247:00 amRNSUpdated Financial Guidance and 2023 Trading
1st Mar 20247:00 amRNSTotal Voting Rights
15th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
1st Feb 20244:48 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSBlock Listing Application
30th Jan 20247:00 amRNSTotal Voting Rights
29th Jan 20248:38 amRNSCompletion of Transaction
26th Jan 20243:09 pmRNSBlock listing application
4th Jan 202411:49 amRNSDirector Declaration
2nd Jan 20247:00 amRNSBlock Listing Return
2nd Jan 20247:00 amRNSTotal Voting Rights
13th Dec 20237:00 amRNS2023 AGM Post Meeting Update Statement
7th Dec 20237:00 amRNSBusiness Update
4th Dec 20237:00 amRNSSigning of agreement to acquire ABL Europe
1st Dec 20237:00 amRNSTotal Voting Rights
24th Nov 20237:00 amRNSGrant of options
16th Nov 20233:32 pmRNSPDMR Dealing – Replacement
14th Nov 20231:43 pmRNSPDMR Dealings
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20236:17 pmRNSHolding(s) in Company
24th Oct 20235:36 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSHolding(s) in Company
11th Oct 202311:33 amRNSPDMR Dealings
4th Oct 20235:09 pmRNSGrant of Options
2nd Oct 20233:06 pmRNSTotal Voting Rights
27th Sep 202312:03 pmRNSPDMR / PCA Dealing
26th Sep 20233:47 pmRNSPDMR Dealings
22nd Sep 202311:42 amRNSPDMR Dealings
20th Sep 202311:42 amRNSDirector Dealings
20th Sep 20237:01 amRNSProject Aquarius
20th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSTotal Voting Rights
22nd Aug 20237:00 amRNSExpanded agreement with Cabaletta Bio
14th Aug 20237:00 amRNSNotice of Interim Results
1st Aug 20237:00 amRNSTotal Voting Rights
3rd Jul 20234:31 pmRNSPDMR Dealings
3rd Jul 20237:00 amRNSOxford Biomedica PLC - Block Listing Return
3rd Jul 20237:00 amRNSTotal Voting Rights
23rd Jun 20235:32 pmRNSResult of AGM
6th Jun 20233:59 pmRNSTotal Voting Rights
15th May 20237:00 amRNSOxford Biomedica launches TetraVecta system
10th May 20237:00 amRNSBlock listing Application
5th May 20237:00 amRNS2023 AGM Notification
2nd May 20237:00 amRNSTotal Voting Rights
28th Apr 20237:59 amRNS2022 Annual Report and Accounts
26th Apr 20237:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.